Suicidal Thoughts and Behavior with Antidepressant Treatment: Reanalysis of the Randomized Placebo-controlled Studies of Fluoxetine and Venlafaxine

Overview

Journal Arch Gen Psychiatry

Specialty Psychiatry

Date 2012 Feb 8

PMID 22309973

Citations 98

Authors

Robert D Gibbons

C Hendricks Brown

Kwan Hur

John Davis

J John Mann

Affiliations

Soon will be listed here.

Abstract

Context: The US Food and Drug Administration issued a black box warning for antidepressants and suicidal thoughts and behavior in children and young adults.

Objective: To determine the short-term safety of antidepressants by standard assessments of suicidal thoughts and behavior in youth, adult, and geriatric populations and the mediating effect of changes in depressive symptoms.

Data Sources: All intent-to-treat person-level longitudinal data of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride and 21 adult trials of venlafaxine hydrochloride.

Study Selection: All sponsor-conducted randomized controlled trials of fluoxetine and venlafaxine.

Data Extraction: The suicide items from the Children's Depression Rating Scale-Revised and the Hamilton Depression Rating Scale as well as adverse event reports of suicide attempts and suicide during active treatment were analyzed in 9185 patients (fluoxetine: 2635 adults, 960 geriatric patients, 708 youths; venlafaxine: 2421 adults with immediate-release venlafaxine and 2461 adults with extended-release venlafaxine) for a total of 53 260 person-week observations.

Data Synthesis: Suicidal thoughts and behavior decreased over time for adult and geriatric patients randomized to fluoxetine or venlafaxine compared with placebo, but no differences were found for youths. In adults, reduction in suicide ideation and attempts occurred through a reduction in depressive symptoms. In all age groups, severity of depression improved with medication and was significantly related to suicide ideation or behavior.

Conclusions: Fluoxetine and venlafaxine decreased suicidal thoughts and behavior for adult and geriatric patients. This protective effect is mediated by decreases in depressive symptoms with treatment. For youths, no significant effects of treatment on suicidal thoughts and behavior were found, although depression responded to treatment. No evidence of increased suicide risk was observed in youths receiving active medication. To our knowledge, this is the first research synthesis of suicidal thoughts and behavior in depressed patients treated with antidepressants that examined the mediating role of depressive symptoms using complete longitudinal person-level data from a large set of published and unpublished studies.

Citing Articles

Resting-State Electroencephalogram Complexity Is Associated With Oral Ketamine Treatment Response: A Bayesian Analysis of Lempel-Ziv Complexity and Multiscale Entropy.

Mitchell J, Anijarv T, Can A, Dutton M, Hermens D, Lagopoulos J Brain Behav. 2024; 14(11):e70166.

PMID: 39607091 PMC: 11603427. DOI: 10.1002/brb3.70166.

Impact of sedative and appetite-increasing properties on the apparent antidepressant efficacy of mirtazapine, selective serotonin reuptake inhibitors and amitriptyline: an item-based, patient-level meta-analysis.

Hieronymus F, Lisinski A, Eriksson E EClinicalMedicine. 2024; 77:102904.

PMID: 39568633 PMC: 11576391. DOI: 10.1016/j.eclinm.2024.102904.

Targeting suicidal ideation in major depressive disorder with MRI-navigated Stanford accelerated intelligent neuromodulation therapy.

Li B, Zhao N, Tang N, Friston K, Zhai W, Wu D Transl Psychiatry. 2024; 14(1):21.

PMID: 38199983 PMC: 10781692. DOI: 10.1038/s41398-023-02707-9.

Integrative Analyses of scRNA-seq, Bulk mRNA-seq, and DNA Methylation Profiling in Depressed Suicide Brain Tissues.

Zhou Y, Xiong L, Chen J, Wang Q Int J Neuropsychopharmacol. 2023; 26(12):840-855.

PMID: 37774423 PMC: 10726413. DOI: 10.1093/ijnp/pyad057.

Psychosis Symptom Trajectories Across Childhood and Adolescence in Three Longitudinal Studies: An Integrative Data Analysis with Mixture Modeling.

Musci R, Kush J, Masyn K, Esmaeili M, Susukida R, Goulter N Prev Sci. 2023; 24(8):1636-1647.

PMID: 37615885 PMC: 10966507. DOI: 10.1007/s11121-023-01581-7.

References

Brown G, Steer R, Henriques G, Beck A . The internal struggle between the wish to die and the wish to live: a risk factor for suicide. Am J Psychiatry. 2005; 162(10):1977-9. DOI: 10.1176/appi.ajp.162.10.1977. View

Brown C, Sloboda Z, Faggiano F, Teasdale B, Keller F, Burkhart G . Methods for synthesizing findings on moderation effects across multiple randomized trials. Prev Sci. 2011; 14(2):144-56. PMC: 3135722. DOI: 10.1007/s11121-011-0207-8. View

Brent D, Oquendo M, Birmaher B, Greenhill L, Kolko D, Stanley B . Familial pathways to early-onset suicide attempt: risk for suicidal behavior in offspring of mood-disordered suicide attempters. Arch Gen Psychiatry. 2002; 59(9):801-7. DOI: 10.1001/archpsyc.59.9.801. View

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J . Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004; 292(7):807-20. DOI: 10.1001/jama.292.7.807. View

Mann J, Emslie G, Baldessarini R, Beardslee W, Fawcett J, Goodwin F . ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2005; 31(3):473-92. DOI: 10.1038/sj.npp.1300958. View

MacKinnon D, Lockwood C, Brown C, Wang W, Hoffman J . The intermediate endpoint effect in logistic and probit regression. Clin Trials. 2007; 4(5):499-513. PMC: 2857773. DOI: 10.1177/1740774507083434. View

Gibbons R, Hur K, Brown C, Davis J, Mann J . Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012; 69(6):572-9. PMC: 3371295. DOI: 10.1001/archgenpsychiatry.2011.2044. View

Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-77. PMC: 3893686. DOI: 10.1176/appi.ajp.2011.10111704. View

Siddique J, Brown C, Hedeker D, Duan N, Gibbons R, Miranda J . Missing Data in Longitudinal Trials - Part B, Analytic Issues. Psychiatr Ann. 2009; 38(12):793-801. PMC: 2722118. DOI: 10.3928/00485713-20081201-09. View

10.

Rush A . STAR*D: what have we learned?. Am J Psychiatry. 2007; 164(2):201-4. DOI: 10.1176/ajp.2007.164.2.201. View

11.

Posner K, Oquendo M, Gould M, Stanley B, Davies M . Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007; 164(7):1035-43. PMC: 3804920. DOI: 10.1176/ajp.2007.164.7.1035. View

12.

Muthen B, Brown H . Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med. 2009; 28(27):3363-85. PMC: 2818509. DOI: 10.1002/sim.3721. View

13.

Oquendo M, Galfalvy H, Russo S, Ellis S, Grunebaum M, Burke A . Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry. 2004; 161(8):1433-41. DOI: 10.1176/appi.ajp.161.8.1433. View

14.

Curran P, Hussong A . Integrative data analysis: the simultaneous analysis of multiple data sets. Psychol Methods. 2009; 14(2):81-100. PMC: 2777640. DOI: 10.1037/a0015914. View